Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: An open-label, multiple-dose, controlled Phase I study in adults

Clinical Therapeutics

Volumn 32, Issue 2, 2010, Pages 328-337

  Schöller Gyüre, Monika ^a   Kakuda, Thomas N ^b   Smedt, Goedele De ^a   Woodfall, Brian ^a   Berckmans, Cindy ^a   Peeters, Monika ^a   Hoetelmans, Richard M W ^a  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Inc   (United States)

Author keywords

etravirine; hepatic impairment; non nucleoside reverse transcriptase inhibitor; pharmacokinetics; TMC125

Indexed keywords

ETRAVIRINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LABORATORY TEST; LIVER CIRRHOSIS; LIVER DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MUSCLE SPASM; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; SIDE EFFECT; SMOKING; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-HIV AGENTS; FEMALE; GERMANY; HUMANS; LINEAR MODELS; LIVER DISEASES; MALE; MIDDLE AGED; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 77649156807     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.02.013     Document Type: Article

References (29)

1. Intelence (etravirine) [prescribing information] (2008), Tibotec, Inc, Yardley, Pa
2. Intelence (etravirine) [product information]. http://emc.medicines.org.uk/medicine/21185/SPC/Intelence/ Accessed November 30, 2009
3. Andries K., Azijn H., Thielemans T., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 48 (2004) 4680-4686
4. Vingerhoets J., Azijn H., Fransen E., et al. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol. 79 (2005) 12773-12782
5. Lazzarin A., Campbell T., Clotet B., et al., DUET-2 Study Group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-Week results from a randomised, doubleblind, placebo-controlled trial. Lancet. 370 (2007) 39-48
6. Madruga J.V., Cahn P., Grinsztejn B., et al., DUET-1 Study Group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-Week results from a randomised, doubleblind, placebo-controlled trial. Lancet. 370 (2007) 29-38
7. Milles A., Cahn P., Molina J.M., et al. Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: Pooled 96-week results. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town South Africa (July 19-22, 2009) Abstract MOPEB036
8. Schöller-Gyüre M., Raoof A., Mannens G., et al. Massbalance of 14C-labelled TMC125 in healthy volunteers. Presented at: 8th International Workshop of Clinical Pharmacology. Budapest, Hungary (April 16-18, 2007) Abstract 78
9. Kakuda T.N., Schöller-Gyüre M., Woodfall B.J., et al. TMC125 in combination with other medications: Summary of drug-drug interaction studies. Presented at: 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (November 12-16, 2006) Abstract PL5.2.
10. Schöller-Gyüre M., Kakuda T.N., Stevens T., et al. Effect of etravirine on cytochrome P450 isozymes assessed by the Cooperstown 5+1 cocktail. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. (October 25-28, 2008) Abstract 3638.
11. Schöller-Gyüre M., Kakuda T.N., Van Solingen R., et al. No clinically relevant effect of etravirine (ETR; TMC125) on digoxin pharmacokinetics in HIV-negative volunteers. Presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, La. (April 7-9, 2008) Abstract P22
12. Schöller-Gyüre M., Boffito M., Pozniak A.L., et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy. 28 (2008) 1215-1222
13. Salmon-Ceron D., Lewden C., Morlat P., et al., Mortality 2000 Study Group. Liver disease as a major cause of death among HIV infected patients: Role of hepatitis C and B viruses and alcohol. J Hepatol. 42 (2005) 799-805
14. Núñez M., and Soriano V. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. Drug Saf. 28 (2005) 53-66
15. Wyles D.L., and Gerber J.G. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction [published correction appears in Clin Infect Dis. 2005;40:913]. Clin Infect Dis 40 (2005) 174-181
16. Damle B., Hewlett Jr. D., Hsyu P.H., et al. Pharmacokinetics of nelfinavir in subjects with hepatic impairment. J Clin Pharmacol. 46 (2006) 1241-1249
17. McCabe S.M., Ma Q., Slish J.C., et al. Antiretroviral therapy: Pharmacokinetic considerations in patients with renal or hepatic impairment. Clin Pharmacokinet. 47 (2008) 153-172
18. Barreiro P., Rodriguez-Novoa S., Labarga P., et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis. 195 (2007) 973-979
19. Pereira S.A., Caixas U., Branco T., et al. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. Br J Clin Pharmacol. 66 (2008) 551-555
20. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60 (1973) 646-649
21. Schöller-Gyüre M., Kakuda T.N., Sekar V., et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 12 (2007) 789-796
22. Division of AIDS Table for Grading Severity of Adult Adverse Experiences; August 1992. http://rcc.techres-intl.com/tox_tables.htm Accessed July 3, 2008
23. Benet L.Z., and Hoener B.A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 71 (2002) 115-121
24. Frye R.F., Zgheib N.K., Matzke G.R., et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther. 80 (2006) 235-245
25. Ohnishi A., Murakami S., Akizuki S., et al. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. J Clin Pharmacol. 45 (2005) 1221-1229
26. Kakuda T.N., Peeters M., Corbett C., et al. Pharmacokinetics and pharmacodynamics of etravirine in treatmentexperienced HIV-1-infected patients: Pooled 48-week results of DUET-1 and DUET-2. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC (October 25-28, 2008)
27. Kakuda T.N., Schöller-Gyüre M., Peeters M., et al. Pharmacokinetics of etravirine are not affected by sex, age, race, treatment duration or use of enfuvirtide in HIV-1-infected subjects. Presented at: XVIIth International AIDS Conference. Mexico City, Mexico (August 3-8, 2008)
28. Katlama C., Haubrich R., Lalezari J., et al., DUET-1, DUET-2 Study Groups. Efficacy and safety of etra-virine in treatment-experienced, HIV-1 patients: Pooled 48 week analysis of two randomized, controlled trials. AIDS. 23 (2009) 2289-2300
29. Aboud M., Castelino S., Back D., and Kulasegaram R. Etravirine plasma levels in a patient with decompensated liver disease. AIDS. 23 (2009) 1293-1295